MedPath

Cardiovascular Biotherapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Phase 1
Conditions
Peripheral Arterial Disease
Stenosis
Intermittent Claudication
Interventions
Drug: Placebo
First Posted Date
2007-01-22
Last Posted Date
2019-11-01
Lead Sponsor
CardioVascular BioTherapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT00424866
Locations
🇺🇸

CVBT Info, Dallas, Texas, United States

FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers

Phase 1
Completed
Conditions
Diabetes
Venous Stasis Ulcers
Chronic Wounds
First Posted Date
2007-01-22
Last Posted Date
2019-11-01
Lead Sponsor
CardioVascular BioTherapeutics, Inc.
Target Recruit Count
8
Registration Number
NCT00425178
Locations
🇺🇸

Warren General Hospital, Warren, Pennsylvania, United States

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Phase 2
Conditions
Coronary Disease
Coronary Heart Disease
Myocardial Ischemia
Coronary Arteriosclerosis
First Posted Date
2005-07-11
Last Posted Date
2019-11-01
Lead Sponsor
CardioVascular BioTherapeutics, Inc.
Target Recruit Count
150
Registration Number
NCT00117936

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.